A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
about
Chronic lymphocytic leukemia: a clinical review including Korean cohortsImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)New strategies in chronic lymphocytic leukemia: shifting treatment paradigmsTetraspanins as therapeutic targets in hematological malignancy: a concise reviewOtlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLEntering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.Emerging therapies for refractory chronic lymphocytic leukemia.New targets for antibody therapy of pediatric B cell lymphomas.Chemotherapy-free treatment in patients with follicular lymphoma.Targeted therapy for chronic lymphocytic leukemia: current status and future directions.Promising therapies for the treatment of chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.The Emerging Role of Tetraspanins in the Proteolytic Processing of the Amyloid Precursor Protein.New targeted therapies for malignant lymphoma based on molecular heterogeneity.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Obinutuzumab for the treatment of indolent lymphomaRecent advances in therapy of chronic lymphocytic leukaemia.Targeting indolent non-Hodgkin lymphoma.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.New emerging therapies in the management of chronic lymphocytic leukemia.Recent therapeutic advances in chronic lymphocytic leukemia.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
P2860
Q26752467-199BA5C5-4B18-4F50-9F30-02BA47505676Q26768154-5479D0B2-89B9-49FF-AFE6-F9157D8440F8Q26828496-5EE57DC8-DF74-4D46-A685-B08194DAEA67Q27002353-1912F9CE-1043-4BB6-80DB-EF25DB6A7CDEQ33417223-B3451C1F-07CC-41DE-A98F-95CED249728CQ33418091-2C79EE26-1248-4B87-B66B-35B173BC582BQ34172063-EC4FFA61-0DFD-4560-A78A-44FFBC913791Q34440110-FB9F6126-2522-481E-AB17-1FA9521A6326Q34498655-63A08836-A813-4C77-9472-32044DB49AF5Q34543066-8329252F-2469-4B4A-88D3-8F09A52EC89BQ37663837-F3E36C67-4B36-41F4-99AA-7DBDD63B89E5Q38207143-55B22807-9468-471E-8100-5D5E5C9C489CQ38242984-3E610B1E-F4A7-461E-A1AA-C12F72AEFC80Q38317235-281CBE0B-683F-4265-93B6-EE4CD27AB7D7Q38331701-4E1E68EA-EE5E-4C21-8359-D498A545B4AEQ38366441-0826171A-F84C-412B-A62F-DBF3BEE816A7Q38543771-A7D85DDF-DE13-4CB6-8C99-D8FC3DEB225AQ38573785-E5252DE3-63B4-44F2-9CC7-0AF4566857BFQ38655388-9DA5FE1D-1A62-4942-91A1-4D23DEE506E7Q38773212-FCFA7A9C-D38A-4B23-812C-D1EF668A0FF7Q38787141-B2858507-22C5-4F12-848D-506963A7932AQ38818283-83C14F57-6B8C-4C51-A3FA-B540FDE49078Q38818380-99C7A12A-B2AC-4961-A3D2-E351620A6140Q38862525-F349B599-8D40-4E9B-B474-69577968B95BQ38917848-7F6980AB-438C-491F-9639-DFC3B330C7BBQ39018189-3036178D-A397-4B86-B04D-666934D2DB00Q39023986-254C1B68-B85B-4CC2-BD27-50BD5894C1AEQ46318389-8E6E4684-FFEE-4018-A4BC-3281471723F0Q47898168-3E4CC3C5-6DF8-437C-9D44-417C69CEFFC3Q49539698-842FE5AA-3A4B-422A-A913-DC2FAD1ACF22
P2860
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase 1 study evaluating the ...... n chronic lymphocytic leukemia
@en
A phase 1 study evaluating the ...... chronic lymphocytic leukemia.
@nl
type
label
A phase 1 study evaluating the ...... n chronic lymphocytic leukemia
@en
A phase 1 study evaluating the ...... chronic lymphocytic leukemia.
@nl
prefLabel
A phase 1 study evaluating the ...... n chronic lymphocytic leukemia
@en
A phase 1 study evaluating the ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P1433
P1476
A phase 1 study evaluating the ...... n chronic lymphocytic leukemia
@en
P2093
Amy J Eisenfeld
Andres Forero
Delva P Deauna-Limayo
Farrukh T Awan
Jeannette E Bannink
John C Byrd
John M Pagel
John P Leonard
Leslie A Andritsos
Richard R Furman
P2860
P304
P356
10.1182/BLOOD-2013-07-512137
P407
P577
2013-12-31T00:00:00Z